April 2013 What predicts response to hepatitis C virus (HCV) treatment? Many things help predict the likelihood of being cured (called sustained virological response or SVR) by pegylated interferon (PEG-IFN) and ribavirin (RBV). Making sure to take all medications as…
February 14, 2013 – Today, on the occasion of Valentine's Day, Médecins du Monde and Treatment Action Group (TAG) are launching an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis…
by Karyn Kaplan The current standard of care for HCV is pegylated interferon (PEG-IFN) and ribavirin. Yet in most countries, this treatment is unaffordable to all but the wealthiest people. In order to stimulate price reductions and increase access, Médecins…
by Tracy Swan It is difficult not to be dazzled by cure rates of up to 100% from interferon-free hepatitis C virus (HCV) trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012…
Grief Is a Sword: A Eulogy for Spencer Cox; A Global Plan to End AIDS Everywhere but at Home ; On the Edge: Uncertainty Grows over HIV Budgets; Data Deluge at AASLD; Beyond ARVs: Advocacy for Non-AIDS Disease Management; TB Zeroes Campaign Achieves Big Win; TAG Welcomes the FDA Approval of the First New Drug for TB in 40 Years; Help Support Inclusion of Pegylated Interferon on the World Health Organization’s Essential Medicines List; Guide to Clinical Trials for People with Hepatitis C.
There are many new hepatitis C drugs being studied in clinical trials. People with hepatitis C have many options to choose from. Whether you have hepatitis C or another medical condition, deciding to participate in a clinical trial can be complicated.
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement
In 2012, the Fulbright Association presented its J. William Fulbright Prize for International Understanding to Médecins Sans Frontières (MSF); the first time this was awarded to an organization, not an individual. Treatment Action Group’s executive director, Mark Harrington, delivered this…
Letter from TAG and civil society organizations undersigned grassroots civil society groups and non-governmental organizations asking for universal access to HCV voluntary testing and treatment.